Document is current
Any future updates will be listed below
-
Authors
Kulkarni, Tejaswini
Zisman, David A.
Shlobin, Oksana A.
Kiely, David G.
DerSarkissian, Maral
Shen, Eric
Maher, Kevin M.
Broderick, Meredith
Scholand, Mary Beth
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05776225 at ClinicalTrials.govDocuments that mention this clinical trial
Study Design and Rationale for the PHINDER Study: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
https://doi.org/10.1007/s41030-025-00307-0
P284 Interim results from PHINDER: pulmonary hypertension screening in patients with interstitial lung disease
https://doi.org/10.1136/thorax-2025-btsabstracts.465
-
Funding
Funding for this research was provided by:
United Therapeutics Corporation
- License Information
-
More Information
Article History
Received: 23 April 2025
Accepted: 26 June 2025
First Online: 25 July 2025
Declarations
:
: Tejaswini Kulkarni reports consultation fees from United Therapeutics and Aileron, speaker/ consultation fees from Boehringer Ingelheim Inc. and Veracyte, consultation/advisory board fees from Avalyn and PureTech Health. David Zisman is on the speaker’s bureau for, and received consultation fees from United Therapeutics Corp. Also, he declares he is partly funded by a generous gift from William and Jean Soman. Zisman was a previous author on the Delphi (Rahaghi, et al.) that was used to create the enrichment criteria for this study. David Kiely reports support from the Sheffield Biomedical Research Centre, consulting fees and other payments from Jansen Pharmaceuticals, Ferrer, Altavant, MSD and United Therapeutics. Oksana Shlobin reports consultancy fees from United Therapeutics, Merck, Janssen and Aerami, payment or honoraria for lectures, presentations, manuscript writing or educational events from Ferrera and United Therapeutics, participation on a data safety monitoring board or advisory board with Janssen, and leadership roles with ACCP/CHEST and World Symposium on Pulmonary Hypertension task force. Shlobin was a previous author on the Delphi (Rahaghi, et al.) that was used to create the enrichment criteria for this study. Maral DerSarkissian is an employee of Analysis Group, Inc. which received research funds for her participation in this study. Eric Shen, Kevin Maher, and Meredith Broderick are employees of United Therapeutics. Mary Beth Scholand reports consultation fees from Boehringer Ingelheim, Genentech, Veracyte, Imvaria, and United Therapeutics. Scholand was a previous author on the Delphi (Rahaghi, et al.) that was used to create the enrichment criteria for this study.
: This study protocol has been approved by the institutional review board at each participating site. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All subjects provided informed consent to participate in the study. For this study, Advarra is the central IRB/main center, but some sites utilize local IRB in addition to or instead of Advarra (see supplementary material for details) and the study was approved by all institutions.
